New Delhi: A new Elecsys AMH Plus-based blood test has been introduced to enable earlier and more accessible diagnosis of Polycystic Ovary Syndrome (PCOS), a condition that remains significantly underdiagnosed among women. The test has been launched by Redcliffe Labs in collaboration with Roche Diagnostics India.
The test uses a simple blood sample to identify Polycystic Ovarian Morphology (PCOM) by measuring Anti-Müllerian Hormone (AMH), offering an alternative to traditional ultrasound-based diagnostic methods.
PCOS affects nearly one in five women of reproductive age in India, while global estimates suggest up to 70 per cent of cases remain undiagnosed. The new test aims to bridge this gap by providing a minimally invasive, cycle-independent, and standardised approach, reducing reliance on transvaginal ultrasound.
Backed by recent global clinical guidelines (2023) and supported by Indian clinical recommendations, AMH is increasingly being recognised as a reliable marker for assessing PCOM. Clinical studies have also demonstrated strong accuracy, making it a promising tool for improving early detection.
Experts note that such innovations could help streamline diagnosis, reduce patient discomfort, and enable timely intervention, particularly in settings where access to specialised imaging remains limited.
The development reflects a broader shift towards accessible, patient-friendly diagnostics in women’s health, with a focus on early identification and proactive management of PCOS.
